Clinical Trial Update: PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes a completed Phase Ib study evaluating buparlisib (BKM120) or dactolisib (BEZ235) in combination with endocrine therapy for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Buparlisib (buparlisib)
• Dactolisib (dactolisib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED